MedTrace Logo

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

NCT03175029 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2025-01-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.

Conditions

Interventions

DRUG

TAC-302

TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.

DRUG

Placebo

Placebo administered orally twice per day after meals, for 12 weeks.

Sponsors & Collaborators

  • Taiho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taiho Pharmaceutical Co., Ltd · Taiho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-09
Primary Completion
2019-11-01
Completion
2020-03-27

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03175029 on ClinicalTrials.gov